



Original Investigation | Geriatrics

Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life

An Individual Participant Data Meta-Analysis

Matthew J. Lennon, MD; Ben Chun Pan Lam, PhD; Darren M. Lipnicki, PhD; John D. Crawford, PhD; Ruth Peters, PhD; Aletta E. Schutte, PhD; Henry Brodaty, MD, DSc; Anbupalam Thalamuthu, PhD; Therese Rydberg-Sterner, PhD; Jenna Najar, MD, PhD; Ingmar Skoog, MD, PhD; Steffi G. Riedel-Heller, MD; Susanne Röhr, PhD; Alexander Pabst, PhD; Antonio Lobo, MD; Concepción De-la-Cámara, MD; Elena Lobo, PhD; Toyin Bello, MSc; Oye Gureje, MBBS, PhD, DSc; Akin Ojagbemi, MBBS, PhD; Richard B. Lipton, MD; Mindy J. Katz, MPH; Carol A. Derby, PhD; Ki Woong Kim, MD, PhD; Ji Won Han, MD, PhD; Dae Jong Oh, MD, PhD; Elena Rolandi, MSc; Annalisa Davin, MSc; Michele Rossi, BS; Nikolaos Scarmeas, MD, PhD; Mary Yannakoulia, MSc, PhD; Themis Dardiotis, PhD; Hugh C. Hendrie, MB, ChB, BSc; Sujuan Gao, PhD; Isabelle Carrière, PhD; Karen Ritchie, PhD; Kaarin J. Anstey, PhD; Nicolas Cherbuin, PhD; Shifu Xiao, MD, PhD; Ling Yue, MD; Wei Li, MD; Maëllenn M. Guerchet, PhD; Pierre-Marie Preux, PhD; Victor Aboyans, MD, PhD; Mary N. Haan, DrPH, MPH; Allison E. Aiello, PhD; Tze Pin Ng, MBBS, PhD; Ma Shwe Zin Nyunt, PhD; Qi Gao, PhD; Marcia Scazufca, PhD; Perminder S. S. Sachdev, MD, PhD

Abstract

IMPORTANCE The utility of antihypertensives and ideal blood pressure (BP) for dementia prevention in late life remains unclear and highly contested.

OBJECTIVES To assess the associations of hypertension history, antihypertensive use, and baseline measured BP in late life (age >60 years) with dementia and the moderating factors of age, sex, and racial group.

DATA SOURCE AND STUDY SELECTION Longitudinal, population-based studies of aging participating in the Cohort Studies of Memory in an International Consortium (COSMIC) group were included. Participants were individuals without dementia at baseline aged 60 to 110 years and were based in 15 different countries (US, Brazil, Australia, China, Korea, Singapore, Central African Republic, Republic of Congo, Nigeria, Germany, Spain, Italy, France, Sweden, and Greece).

DATA EXTRACTION AND SYNTHESIS Participants were grouped in 3 categories based on previous diagnosis of hypertension and baseline antihypertensive use: healthy controls, treated hypertension, and untreated hypertension. Baseline systolic BP (SBP) and diastolic BP (DBP) were treated as continuous variables. Reporting followed the Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data reporting guidelines.

MAIN OUTCOMES AND MEASURES The key outcome was all-cause dementia. Mixed-effects Cox proportional hazards models were used to assess the associations between the exposures and the key outcome variable. The association between dementia and baseline BP was modeled using nonlinear natural splines. The main analysis was a partially adjusted Cox proportional hazards model controlling for age, age squared, sex, education, racial group, and a random effect for study. Sensitivity analyses included a fully adjusted analysis, a restricted analysis of those individuals with more than 5 years of follow-up data, and models examining the moderating factors of age, sex, and racial group.

RESULTS The analysis included 17 studies with 34 519 community dwelling older adults (20 160 [58.4%] female) with a mean (SD) age of 72.5 (7.5) years and a mean (SD) follow-up of 4.3 (4.3) years. In the main, partially adjusted analysis including 14 studies, individuals with untreated hypertension had a 42% increased risk of dementia compared with healthy controls (hazard ratio [HR], 1.42; 95%

(continued)

Key Points

Question Are blood pressure (BP) and treatment for hypertension in late life associated with dementia risk?

Findings In this meta-analysis including individual participant data from 34 519 community dwelling older adults in 17 studies, untreated hypertension was associated with a greater risk of dementia compared with treated hypertension, and this association was not modified by age. Participants with treated hypertension had no greater dementia risk compared with healthy controls, and baseline BP did not moderate the reduced dementia risk in participants with treated hypertension.

Meaning The findings indicate that ongoing antihypertensive therapy throughout late life is an important part of dementia prevention.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

CI 1.15-1.76; $P = .001$) and 26% increased risk compared with individuals with treated hypertension (HR, 1.26; 95% CI, 1.03-1.53; $P = .02$). Individuals with treated hypertension had no significant increased dementia risk compared with healthy controls (HR, 1.13; 95% CI, 0.99-1.28; $P = .07$). The association of antihypertensive use or hypertension status with dementia did not vary with baseline BP. There was no significant association of baseline SBP or DBP with dementia risk in any of the analyses. There were no significant interactions with age, sex, or racial group for any of the analyses.

CONCLUSIONS AND RELEVANCE This individual patient data meta-analysis of longitudinal cohort studies found that antihypertensive use was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls.

JAMA Network Open. 2023;6(9):e2333353. doi:10.1001/jamanetworkopen.2023.33353

Introduction

Hypertension is the most prevalent risk factor for dementia, affecting more than 1 billion people worldwide.¹ Midlife hypertension is associated with an approximately 60% increased risk of all-cause dementia² and an approximately 25% increased risk of Alzheimer dementia.³ However, in late life, this association was not consistently observed, and most studies have found either no association or that higher systolic blood pressure (SBP) or diastolic blood pressure (DBP) was associated with lower risk of dementia.⁴

A recent individual participant data (IPD) meta-analysis⁵ including 17 286 participants (age range, 65-95 years) found that higher BP may have a protective association against dementia. The meta-analysis by van Dalen et al⁵ found a negative, approximately linear association, indicating that higher SBP was associated with lower risk of dementia and the low point of risk was at an SBP of approximately 185 mm Hg, although this result was modified by age.⁵ Other studies of late-life BP have found U-shaped associations between BP and dementia risk, but estimates of the lowest-risk BPs vary widely.⁶ Aside from differential associations with changing age, studies have also indicated that the association of BP with dementia risk is moderated by sex⁷⁻¹⁴ and racial^{15,16} grouping. A systematic review⁷ found that for women, higher midlife SBP, but not late-life SBP, was associated with greater risk of dementia compared with men in 6 of 7 studies. A large study¹⁷ using US Medicare data examining late-life (age >65 years) adults, including 320 720 Black adults and 3 121 553 White adults, found that hypertension was associated with a greater AD risk in Black populations than in White populations. Several large studies^{15,16} examining cognitive outcomes have corroborated this finding.

While population-based studies of older persons (age >60 years) have regularly found higher BPs to be associated with lower dementia risk, clinical trials of antihypertensives indicate that lower BP targets produce the best cognitive outcomes.^{8,18,19} A 2022 IPD meta-analysis²⁰ of randomized clinical trials including 28 008 participants found an adjusted odds ratio of 0.87 favoring treatment of hypertension for dementia risk reduction. There were no differences between male and female outcomes, although age significantly moderated the association, with considerably less benefit found in participants aged 80 years or older compared with those aged 61 to 70 years.

However, a key challenge with randomized clinical trials is their limited generalizability.^{21,22} They have strict inclusion criteria that exclude many participants, particularly in highly comorbid, elderly populations, and they are run almost exclusively in developed nations. Thus, there is a need for inclusive longitudinal studies that incorporate diverse populations to inform guidelines. In this study, we performed an IPD meta-analysis on a harmonized data set of 17 longitudinal studies²³⁻³⁹ from across the world to delineate the precise associations of BP and antihypertensive use with the risk of

progressing to dementia, as well as to understand the differential associations of BP with dementia in various age, sex, and racial groups.

Methods

For this IPD meta-analysis, ethics approval was granted by the University of New South Wales Human Research Ethics Committee. Each contributing study had individual ethics approval from their respective institutions, and participants in each study provided informed consent (eTable 1 in Supplement 1). This study is presented according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses of Individuals Participant Data (PRISMA-IPD) reporting guidelines.⁴⁰

Contributing Studies

Our analyses included 17 studies²³⁻³⁹ and 34 519 participants from the Cohort Studies of Memory in an International Consortium (COSMIC), which has been previously described in detail.⁴¹⁻⁴⁴ All studies were longitudinal, population-based studies of aging that included measures of cognition and dementia status (Table 1). The cohorts were from 16 countries: US,^{27,31,35} Brazil,³⁷ Australia,^{34,38} China,²⁹ Korea,²⁵ Singapore,³⁶ Central African Republic,²⁶ Republic of Congo,²⁶ Nigeria,^{27,28} Germany,³³ Spain,³⁹ Italy,²⁴ France,²³ Sweden,³² and Greece.³⁰ They had various assessment schedules (2-16 waves) and follow-up durations (2-15 years) (Table 1). Further descriptions of the studies, including covariates and harmonization protocols, are detailed in eTables 2 through 8 in Supplement 1.

Measures of BP, Hypertension History, Antihypertensive Use, and Covariates

All studies had data on self-reported diagnosis of hypertension, and 14 studies^{23-26,29-32,34-39} included antihypertensive use at baseline. All studies had between 1 and 3 direct measures of BP at baseline, obtained with participants seated. Details on the methods of BP measurement in each study are in eTable 5 in Supplement 1. For studies with more than 1 measure of BP at each wave, the means of those measures (seated only) were taken. Participants with BP 3 SDs from the overall mean across studies were excluded as outliers (ie, SBP: <73.1 mm Hg or >204.1 mm Hg; DBP: <45.1 mm Hg or >114.4 mm Hg). Numbers and percentages of excluded participants can be found in eTable 2 in Supplement 1. Covariates included age, sex, education level, race, body mass index, diabetes status, hypercholesterolemia, and smoking status. Race was self-reported in the individual studies and categorized as Asian, Black, White, and other (encompassing a range of different groups that did not fit within the other categories, eg, American Indian or First Nations Australian). Race was included in the analyses because previous studies have found that hypertension is differentially associated with dementia risk in different racial groups. The categorization and harmonization processes are described in eTables 5 through 7 in Supplement 1.

Dementia Outcome

The key outcome for this study was all-cause dementia. Most studies diagnosed dementia using *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition) (*DSM-IV*) criteria, although some used *Diagnostic and Statistical Manual of Mental Disorders* (Third Edition Revised) (*DSM III-R*) criteria (eTable 8 in Supplement 1). Dementia onset was assigned a date midway between the assessment date when dementia was first diagnosed and the previous assessment date. Three studies²³⁻²⁵ provided dementia diagnosis dates that occurred in medical visits outside of the formal study, and these dates were treated as dates of dementia onset. Participants with dementia at baseline, as defined by each study, were excluded from our analyses.

Statistical Analysis

For each of our analyses, a 1-step IPD approach was used, ie, models were run for all participants in a combined data set with a random-effect term for study, rather than running the models in individual

Table 1. Summary of Demographics at Baseline and Dementia Rates of the 17 Studies Included in Cohort Studies of Memory in an International Consortium After Exclusions

Study	Study name	Main racial group (country)	Age, mean (SD), y	Male sex, %	Education, mean (SD), y	Maximum waves, No.	Follow-up, y Maximum, No.	Blood pressure, Mean (SD), mm Hg		Hypertension status, No. (%)	Dementia, No. (%)	Time to dementia diagnosis, mean (SD), y
								Systolic	Diastolic			
Xiao et al, ²⁹ 2016	Chinese Longitudinal Aging Study	Asian (China)	71.1 (7.8)	45.4	7.7 (5.3)	3	7.2	129.5 (15.2)	77.9 (8.7)	HC: 1318 (51.5); UCH: 11 (0.4); TH: 1108 (43.3); UTH: 121 (4.7)	60 (2.8)	0.5 (0.1)
Guerchet et al, ²⁶ 2014	Epidemiology of dementia in Central Africa	Black (Central African Republic and Republic of Congo)	73.1 (6.6)	41.1	2.0 (3.7)	4	2.9	142.1 (26.7)	80.9 (13.4)	HC: 0; UCH: 0; TH: 175 (38); UTH: 286 (62)	19 (5.9)	1.5 (0.8)
Dardiotis et al, ³⁰ 2014	The Hellenic Longitudinal Investigation of Aging and Diet	White (Greece)	72.8 (5.5)	40.1	8.1 (5)	2	7.3	131.7 (17.7)	77.4 (9.9)	HC: 480 (26); UCH: 165 (8.9); TH: 1114 (60.3); UTH: 89 (4.8)	62 (3.3)	1.6 (0.4)
Hendrie et al, ²⁷ 2001	Indianapolis-Ibadan Study	Black (Nigeria)	73.6 (5.9)	27.8	1.2 (3.2)	7	17.7	155.3 (32.7)	85.9 (16)	NA	216 (13.1)	5.6 (3.9)
Hendrie et al, ²⁷ 2001	Indianapolis-Ibadan Study	Black (US)	75.7 (6)	33.4	11.0 (3.1)	7	17.4	146.9 (22.2)	80.3 (11.8)	NA	262 (18)	5.2 (3.8)
Katz et al, ³¹ 2011	Einstein Aging Study	Black and White (US)	78.1 (5.3)	38.2	13.2 (3.6)	16	19.6	134.1 (15.9)	77.4 (8.5)	HC: 591 (29.7); UCH: 207 (10.4); TH: 1019 (51.2); UTH: 173 (8.7)	153 (7.4)	3.8 (3.3)
Ritchie et al, ²³ 2010	Etude Santé Psychologique et Traitement	White (France)	73.1 (5.5)	41.6	10.2 (3.8)	4	9	140.9 (17.4)	79.7 (9.9)	HC: 1191 (54.8); UCH: 182 (8.4); TH: 766 (35.2); UTH: 36 (1.7)	209 (9.6)	6.9 (4.5)
Rydborg Sterner et al, ³² 2019	Gothenburg H70 Birth Cohort Studies	White (Sweden)	73.3 (4.9)	28.9	9.7 (3.7)	3	10.7	155.6 (21.8)	84.5 (11.3)	HC: 483 (57.6); UCH: 86 (10.3); TH: 239 (28.5); UTH: 30 (3.6)	124 (15.8)	5.9 (2.8)
Guaita et al, ²⁴ 2013	Brain Ageing in Abbiategrasso	White (Italy)	72.2 (1.3)	46.0	6.8 (3.3)	2	3.3	141.7 (17.5)	78.9 (8.4)	HC: 444 (35); UCH: 63 (5); TH: 729 (57.4); UTH: 34 (2.7)	59 (4.6)	2.4 (1)
Han et al, ²⁵ 2018	Korean Longitudinal Study on Cognitive Aging and Dementia	Asian, (Korea)	69.9 (6.6)	43.6	8.2 (5.3)	4	7.1	126.2 (14.8)	77.9 (9.2)	HC: 1137 (29.5); UCH: 161 (4.2); TH: 2233 (58); UTH: 320 (8.3)	226 (3.7)	2.6 (1.5)
Reidel-Heller et al, ³³ 2001	Leipzig Longitudinal Study of the Aged	White (Germany)	81.5 (4.9)	25.9	11.9 (1.7)	7	16	158.6 (24.3)	86.1 (16.2)	NA	229 (23.2)	3.6 (2.7)
Anstey et al, ³⁴ 2012	Personality and Total Health Through Life Study	White (Australia)	62.5 (1.5)	51.5	13.7 (2.8)	4	13.9	139.8 (19.5)	83 (10.7)	HC: 1456 (58.7); UCH: 0; TH: 822 (33.1); UTH: 202 (8.1)	80 (3.2)	8.9 (2.6)
Haan et al, ³⁵ 2003	Sacramento Area Latino Study on Aging	Mexican origin (US)	70.4 (6.8)	41.6	7.3 (5.3)	7	9.4	138.5 (19.3)	75.9 (10.6)	HC: 552 (32.5); UCH: 0; TH: 719 (42.3); UTH: 429 (25.2)	116 (6.8)	1 (0)

(continued)

Table 1. Summary of Demographics at Baseline and Dementia Rates of the 17 Studies Included in Cohort Studies of Memory in an International Consortium After Exclusions (continued)

Study	Study name	Main racial group (country)	Age, mean (SD), y	Male sex, %	Education, mean (SD), y	Maximum waves, No.	Maximum No.	Follow-up, y		Blood pressure, Mean (SD), mm Hg		Hypertension status, No. (%)	Dementia, No. (%)	Time to dementia diagnosis, mean (SD), y
								Mean (SD)	Maximum	Systolic	Diastolic			
Feng et al, ³⁶ 2010	Singapore Longitudinal Aging Study	Asian (Singapore)	68 (5.6)	38.9	6.2 (4.6)	3	4.6	2 (1.7)	135 (17.2)	81.5 (9.1)	HC: 999 (50.7); UCH: 5 (0.3); TH: 883 (44.8); UTH: 82 (4.2)	13 (3.3)	3.1 (0.7)	
Scazufca et al, ³⁷ 2008	São Paulo Aging & Health Study	Multiple (Brazil)	72 (6.1)	39.5	2.5 (3)	2	4.1	1.8 (0.9)	145.7 (25.7)	86 (13.6)	HC: 378 (19.6); UCH: 0; TH: 1142 (59.3); UTH: 407 (21.1)	38 (2.1)	2 (0)	
Sachdev et al, ³⁸ 2010	Sydney Memory and Aging Study	White (Australia)	78.8 (4.8)	44.8	11.6 (3.5)	4	6.8	4.6 (2.1)	144.6 (20.8)	81.8 (10.8)	HC: 306 (29.6); UCH: 98 (9.5); TH: 570 (55.2); UTH: 59 (5.7)	178 (17.2)	4.8 (2.2)	
Lobo et al, ³⁹ 2005	Zaragoza Dementia Depression Project	White (Spain)	73.9 (9.3)	42.9	7.1 (3.8)	3	6.7	2.9 (2.1)	141.3 (18.7)	79.1 (11.2)	HC: 123 (6.9); UCH: 0; TH: 1410 (79.3); UTH: 246 (13.8)	137 (3.1)	2.2 (1.2)	
Hall et al, ²⁸ 1998	Ibadan Study of Aging (ISA)	Black (Nigeria)	78.2 (8.8)	49.9	4.1 (5.2)	4	6	2 (0)	156.5 (26.6)	85.1 (13.6)	NA	51 (2.8)	0.7 (0.4)	
Total	NA	NA	72.5 (7.7)	41.6	8.2 (5.4)			4.3 (4.3)	138.7 (21.5)	80.2 (11.3)	HC: 10402 (35.5); UCH: 1293 (4.4); TH: 14759 (50.3); UTH: 2881 (9.8)	2232 (6.5)	4.1 (3.5)	

Abbreviations: HC, health controls; NA, not applicable; TH, treated with antihypertensives; UCH, uncertain hypertension status; UTH, untreated hypertension.

studies and pooling them using a random-effects meta-analysis. This approach was used because our meta-analyses included small studies with low event rates, where interrogation of interaction effects has reduced power in 2-step approaches.⁴⁵ Hypertension history was examined as a dichotomous variable, but its association was considerably modified by treatment status (eTable 9 in [Supplement 1](#)); thus, our main analysis focused on a categorical variable for hypertension based on both reported hypertension history and antihypertensive use. There were 4 possible groups defined by this variable: no hypertension history while not using an antihypertensive at baseline, classified as healthy control participants; no hypertension history while using an antihypertensive at baseline, classified as uncertain hypertension; reporting hypertension history while using an antihypertensive at baseline, classified as treated hypertension; and reporting hypertension history while not using an antihypertensive at baseline, classified as untreated hypertension. Given that individuals with no reported hypertension history who were using an antihypertensive had an unclear hypertension history, they were excluded from this part of the analysis (1296 participants [4.2%]) (eMethods in [Supplement 1](#)). These groupings formed a key part of our analysis, and as such, a between-group comparison of characteristics was performed (eTable 4 in [Supplement 1](#)). Diagnosis of hypertension requires at least 2 BP measures taken at least 1 month apart⁴⁶; hence, the single measure of baseline BP was not included in our definition of hypertension and antihypertensive status.

Regarding continuous measures of BP, SBP and DBP were centered on the overall mean (ie, SBP: 140 mm Hg; DBP: 80 mm Hg) and divided by 5 (ie, measured in units of 5 mm Hg) to ensure effect sizes would be comparable with other covariates. Previous studies have shown that BP has a U-shaped or parabolic association with dementia.^{5,6} These potential nonlinear associations were examined using natural splines terms for SBP and DBP, with 2 to 4 degrees of freedom according to optimal fit (using Akaike Information Criteria and Bayesian Information Criteria). Similarly, studies have found that risk of dementia increases parabolically rather than linearly with age.⁴⁷ Thus, age was centered on the overall mean (ie, 73 years), and both linear and quadratic age terms (age and age squared) were included in all analyses. Participants younger than 60 years were excluded from the study as they were not considered to be in late life.

Mixed-effects Cox proportional hazards survival models were used to assess the association between various measures and progression to dementia. The first analysis examined dementia risk associated with hypertension and antihypertensive status. The second assessed the associations of baseline SBP and DBP with dementia using natural splines to model the association. Initially, models including continuous BP parameters and hypertension and antihypertensive status, as well as their interaction terms, were examined, but these terms were not included in later models based on poor model fit, number of excluded participants, and lack of interaction significance.

The main analysis included as covariates only age, age squared, sex, education, racial group, and a random intercept term for study. This parsimonious, partially adjusted model was adopted as the main analysis to minimize the exclusion of studies, particularly from lower socioeconomic regions, which were more frequently lacking the other covariates. Further analyses were performed to assess the robustness of our results. First, a fully adjusted analysis was run, controlling additionally for body mass index, hypercholesterolemia, diabetes, and smoking status, using only participants and studies in which these variables were available. Second, a restricted analysis excluding individuals with less than 5 years of follow-up was run. This step was taken because dementia develops over many years; thus, occurrence of dementia within several years of baseline is likely caused by factors considerably prior to the study baseline. Third, to assess individual contributions of each of the studies and heterogeneity between studies, the main model was run within each individual study and results were examined for heterogeneity or outliers. Finally, to assess possible moderating factors of age, sex, and racial group, interactions with these variables were included in separate models. Further details of the interaction analyses are included in the eMethods in [Supplement 1](#).

The Sydney COSMIC team generated the harmonized data set and ran the mixed effects Cox regressions using the `coxme`⁴⁸ and `splines` packages in R statistical software version 4.0.3. *P* values were 2-sided, and *P* = .05 was considered significant. Data were analyzed from January to April 2023.

Results

Participant Characteristics

Of 34 519 participants in 17 studies²³⁻³⁹ included in the analysis, the mean (SD) age at baseline was 72.5 (7.5) years and 20 160 participants (58.4%) were female (Table 1). Participants had a mean (SD) 8.2 (5.4) years of education, and the mean (SD) follow-up time was 4.3 (4.3) years. At baseline, the mean (SD) SBP was 138.7 (21.5) mm Hg and DBP was 80.2 (11.3) mm Hg. Of the hypertensive and antihypertensive groups, 10 402 participants (35.5%) were healthy controls, 1293 participants (4.4%) had uncertain hypertension and were excluded, 14 759 participants (50.3%) had treated hypertension, and 2881 participants (9.8%) had untreated hypertension. At baseline, there were 2884 participants with dementia who were excluded from analysis. The mean (SD) time to dementia diagnosis was 4.X (3.5) years, although this metric varied considerably by study (Table 1).

History of Hypertension and Antihypertensive Use

The main analysis in 14 studies^{23-26,29-32,34-39} found that participants with untreated hypertension had a significantly higher risk of dementia compared with healthy controls (HR, 1.42; 95% CI, 1.15-1.76; $P = .001$) and those with treated hypertension (HR, 1.26; 95% CI, 1.03-1.54; $P = .03$) (Figure 1 and Table 2). There was no significant difference in risk in participants with treated hypertension compared with healthy controls (HR, 1.13; 95% CI, 0.99-1.28; $P = .07$). In the fully adjusted analysis including 9 studies,^{23-26,31,34-37} these results were replicated with similar effect sizes, but in the analysis restricted to participants with more than 5 years of follow-up (10 studies^{23,25,29-32,34-36,39}), the findings were no longer significant. In the 2-step random-effects meta-analysis, comparisons of treated and untreated hypertension groups showed low heterogeneity of estimates between studies ($I^2 = 7.7%$), whereas analyses comparing participants with treated and untreated hypertension with healthy controls had a greater level of heterogeneity (treated hypertension: $I^2 = 85.6%$; untreated hypertension: 57.1%) (eTable 10 in Supplement 1).

Interaction analyses found no significant moderation by age, sex, or race (Figure 1; eTable 11 in Supplement 1). Despite there being no significant moderation by age, treated hypertension was associated with increased risk of dementia at ages 60 and 70 years but not at ages 80 or 90 years (Figure 1; eTable 12 in Supplement 1). The greater risk associated with untreated hypertension compared with healthy controls was consistent throughout the various age, sex, and racial groups.

Baseline BP

In the main, partially adjusted analysis, there were no significant linear or nonlinear associations of baseline SBP or DBP with dementia risk (Table 2 and Figure 2A and B). This finding was confirmed by the fully adjusted model as well as the analysis examining only participants with greater than 5 years of follow-up data (Figure 2C-F). In the 2-step, random-effects meta-analysis, the heterogeneity of the estimates across studies was moderate to small (I^2 for SBP = 24.1%; I^2 for DBP = 46.9%) (eTable 9 in Supplement 1). There were no significant interactions between age, sex, or racial group for SBP or DBP natural splines terms (eTable 13 in Supplement 1). There were no significant interactions between either SBP or DBP and the HT/AHT status of participants indicating their independence (eTable 14 and eTable 15 in Supplement 1).


Discussion

Antihypertensive Use and Dementia Risk in Late Life

This IPD meta-analysis found that older adults with untreated hypertension had significantly increased risk of dementia compared with healthy controls and individuals with treated hypertension. Clinical trials examining antihypertensive use in populations with hypertension have tended to find a small association of treatment with reduced risk of dementia.⁴⁹ In the 2022 IPD meta-analysis by Perters et al²⁰ of 7 clinical trials with 28 008 participants, participants with treated

hypertension had a 13% reduced risk of dementia compared with those with untreated hypertension. Peters et al²⁰ stratified for age and found that the largest association was in adults aged 60 to 70 years with hypertension, with no significant associations with antihypertensive use found in adults aged 71 to 80 years and older than 80 years. By contrast, our study found that even at the ages of 70 and 80 years, there was a significantly higher dementia risk in individuals with untreated hypertension compared with the treated hypertension group. A meta-analysis of longitudinal cohort studies by Ou et al,⁵⁰ found that individuals who used antihypertensive in late life (age >65 years) had a 21% lower dementia risk compared with individuals with untreated hypertension, similar to the findings in our study. It is interesting that cohort studies tend to reflect a larger risk difference between treated and untreated hypertension than clinical trials. This may be related to discrepancies in treatment duration, given that patients in cohort studies have been using medications historically (ie, up to many decades), whereas patients in clinical trials have generally been using the medication only for the duration of the trial (eg, only a few years). Alternatively, risk differences between people with treated vs untreated hypertension may be inflated in cohort studies by a number of nonrandom

Figure 1. Association of Hypertension (HTN) and Antihypertensive Status With the Risk of All-Cause Dementia



The x-axis is in log2 scale. The main analysis (partially adjusted) included covariates of age, age squared, sex, education, and racial group. The fully adjusted analysis included additional covariates of body mass index, smoking status, history of hypercholesterolemia, and diabetes. Each of the other analyses applied the partially adjusted model. The P values show the size of the interaction effect for age, sex, and racial group with treated HTN (compared with healthy controls) and untreated HTN (compared with healthy controls). Age was treated as a continuous variable, sex as a categorical variable, and racial group as a categorical variable with 3 major groups (Asian, Black, and White). The P values show the significance of the interaction term. The interaction P values used White participants as the main comparison group in the racial analysis (as this was the largest group included). HR indicates hazard ratio.

confounders, including poorer health literacy, lower socioeconomic status, greater comorbidity, and reduced access to care.⁵¹

For participants with treated hypertension, our study found that throughout late life, there was no increased risk of dementia compared with healthy controls, and this result was not significantly altered by age, sex, or race. These results corroborated the findings of a meta-analysis including 71 994 participants by Ou et al⁵⁰ that found no association between late-life hypertension and dementia, a finding also supported by earlier meta-analyses.^{52,53} Whereas some studies have suggested that hypertension was associated with greater dementia risk in Black populations⁵⁰ and in males, our study found no significant differences between racial or sex groups. Epidemiological studies have consistently found greater prevalence of hypertension and vascular disease in Black populations.^{54,55} However, multivariate analyses of cardiovascular outcomes indicate that clinical, environmental, and socioeconomic factors, rather than genetic or intrinsic racial differences, explain cardiovascular differences.⁵⁶ Similarly, our study found that while hypertension exposure was greater in Black populations, its association with dementia risk was not significantly different. This finding is reassuring, insofar as it indicates that the similar treatments are likely to be similarly effective in different racial groups.

Baseline BP and History of Hypertension and Antihypertensive Use

This study found that baseline SBP and DBP did not significantly modify the association of hypertension and antihypertensive use status with dementia risk. Similarly, a meta-analysis of clinical trials by Peters et al²⁰ found that treatment was not modified by baseline systolic BP tertiles,

Table 2. Summary of Cox Proportional Hazards Models Examining Associations of Hypertension and Antihypertensive Status and Baseline Blood Pressure With All-Cause Dementia

Group	Dementia risk		Fully adjusted analysis ^b		Restricting to participants with >5 y follow-up	
	Main analysis ^a HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Hypertension status ^c						
Treated hypertension (vs healthy controls)	1.13 (0.99-1.28)	.07	1.04 (0.88-1.22)	.64	1.14 (0.97-1.35)	.12
Untreated hypertension (vs healthy controls)	1.42 (1.15-1.76)	.001	1.37 (1.04-1.81)	.03	1.30 (0.97-1.76)	.08
Untreated hypertension (vs treated hypertension)	1.26 (1.03-1.54)	.03	1.32 (1.01-1.72)	.04	1.14 (0.85-1.52)	.37
Baseline blood pressure, mm Hg ^d						
Systolic						
100	1.06 (0.87-1.30)		1.07 (0.82-1.38)		0.91 (0.70-1.20)	
120	1.01 (0.94-1.09)		1.00 (0.91-1.10)		0.96 (0.88-1.05)	
140	0.99 (0.95-1.03)	.94	1.01 (0.95-1.06)	.89	1.03 (0.99-1.07)	.77
160	0.98 (0.90-1.08)		1.00 (0.86-1.15)		1.05 (0.94-1.17)	
180	0.98 (0.88-1.10)		0.93 (0.79-1.10)		1.00 (0.87-1.16)	
Diastolic						
60	1.05 (0.88-1.25)		1.02 (0.78-1.34)		1.06 (0.83-1.34)	
70	1.04 (0.97-1.10)		1.01 (0.94-1.08)		1.03 (0.94-1.13)	
80	0.97 (0.94-0.99)	.16	0.98 (0.94-1.01)	.72	0.97 (0.94-1.00)	.43
90	0.96 (0.90-1.02)		1.00 (0.93-1.08)		0.97 (0.89-1.07)	
100	1.08 (0.97-1.20)		1.11 (0.97-1.28)		1.10 (0.98-1.24)	

Abbreviation: HR, hazard ratio.

^a The models were all adjusted for age, age squared, sex, education, and racial group.

^b The fully adjusted analysis included additional covariates of body mass index, smoking status, history of hypercholesterolemia, and diabetes.

^c The main analysis included 14 studies,^{23-26,29-32,34-39} 20 381 participants, and 1212 events. The fully adjusted analysis included 9 studies,^{23-26,31,34-37} 12 449 participants, and 784 events. Analysis restricted to participants with more than 5 years of follow-up included 10 studies,^{23,25,29-32,34-36,39} 7266 participants, and 669 events.


^d The main analysis included 17 studies,²³⁻³⁹ 27 508 participants, and 1668 events. The fully-adjusted analysis included 9 studies,^{25,26,30,31,34-36,38} 10 589 participants, and 725 events. The analysis restricted to participants with more than 5 years of follow-up included 13 studies,^{23,25,27,29-35,38,39} 9892 participants, and 887 events. P values for the baseline blood pressure natural splines were computed by comparing the fit of the model with and without the natural splines terms.

quartiles, or quintiles. By contrast, an IPD meta-analysis of 31 090 adults older than 55 years by Ding et al,⁵⁷ found that antihypertensives were associated with dementia risk reduction only in individuals with high baseline BP and not in the group with BP within reference ranges. The challenge with this bivariate grouping is that it eschews nuance, potentially missing differential associations within smaller BP groups and not capturing nonlinear differences in baseline BP interactions, which our study is able to do. Our findings indicate that baseline BP, being a cross-sectional snapshot of a highly variable⁵⁸ biomarker, is of limited significance when making decisions to continue antihypertensive treatment for dementia risk reduction.

Late-Life Baseline BP and Dementia Risk

Our study found no significant association between baseline SBP or DBP in late life and dementia risk in any of the analyses. While this corroborates a panoply of previous studies,^{50,52,59-62} the field remains highly contested, with studies finding that high BP was associated with either an increased^{63,64} or decreased^{5,8,18,19} dementia risk. A number of studies have also found U-shaped associations between dementia risk and BP, but the lowest risk points for these associations vary enormously. In an IPD meta-analysis by Van Dalen et al,⁵ the lowest dementia risk was found at an SBP of 185 mm Hg and a DBP of 139 mm Hg, whereas for the Chicago Health and Aging Project,⁶ the lowest risk was found at an SBP of 138 mm Hg and a DBP of 77 mm Hg.

Figure 2. The Associations of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) With Dementia Risk



In all models, SBP and DBP were centered at the overall mean (SBP: 140 mm Hg; DBP: 80 mm Hg), and all hazard ratios (HRs) represent within-group risk relative to this overall mean; shading indicates 95% CI. A restricted cubic splines model was applied. The partially adjusted analysis included the covariates of age, age squared, sex, education, racial group, and a random effect for study. The fully adjusted analysis included additional covariates of body mass index, smoking status, history of hypercholesterolemia, and diabetes.

What sense can be made of these conflicting results, particularly in light of our study? BP in late life is a highly variable biomarker^{65,66} when measured multiple times within a day⁶⁷ or across annual assessments.⁶⁸ Reasons for this include the white coat effect,⁶⁹ interclinician BP measurement differences, diurnal variation, and late-life biological reasons, including poorer autoregulation⁷⁰ and atherosclerosis.⁷¹ It is also the case that aging-associated vascular calcification and atherosclerosis make BP, and particularly SBP, less reflective of central BP,⁷² which is the measure of greatest significance to cerebral health. The second consideration is that high or low late-life BP will affect individuals differently depending on their vascular history, such as whether midlife hypertension is followed by late life hypotension or hypertension.⁷³⁻⁷⁵ A third consideration is reverse causality. Some argue that lower BPs in late life may cause dementia and cognitive decline, but there is good evidence that dementia and the associated loss of central vascular control, weight loss, and ill health may cause lower BPs.⁷⁰ Given these complex and not fully understood effects, it is unsurprising that there has been such a diversity of results. An IPD meta-analysis by Peters et al²⁰ found that BP reduction in late life was associated with diminished dementia risk down to an SBP of 100 mm Hg and a DBP of 70 mm Hg. Our study, in combination with these results, provides the strongest data yet for the importance of antihypertensive use even in late life^{21,22} and that more than a single late-life BP measure is needed to guide risk stratification and treatment decisions.

Limitations

This study has some limitations, with the primary limitation being variability in cohort study design. Definitions of hypertension change over time and vary across locations, leading to potential differences in diagnosis. Similarly, the cohort studies we included varied in the cognitive instruments and criteria for dementia used (including *DSM-III-R*, *DSM-IV* and *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10]*). Furthermore, studies with more regular follow up periods likely capture a more accurate date of dementia onset, which may have also altered results by modifying the length of diagnosis in various studies. The brief time to onset of dementia in some of the studies suggests the presence of baseline cognitive impairment. Individuals in the early stages of dementia may engage less with medical services or forget to take medications; thus, the cognitive impairment may contribute to undertreatment of hypertension rather than the reverse. We did not have the data to control for some confounders that may contribute to differences in dementia risk between treated and untreated hypertension, including socioeconomic status and poor management of other health conditions. Clearly, individuals with better health literacy and more access to medications will have a panoply of other differences that may contribute to reduced dementia risk. We also did not have data on competing events to dementia, such as death and stroke, which may also modify its association with antihypertensive use. Our study did not provide detail on the classes or doses of antihypertensives used. Previous studies have indicated that angiotensin II receptor blockers may reduce dementia risk more than other types of antihypertensives,⁷⁶ but we did not have information on antihypertensive class to investigate this potentially important moderating factor. Additionally, our classification of participants into 4 broad racial groups does not consider the ethnic and genetic diversity that exists within each of these.

Conclusion

In this IPD meta-analysis with data from 16 countries, we found that hypertension was a risk factor associated with dementia in late life. Antihypertensive use was associated with decreased dementia risk in late-life individuals with hypertension; thus, dementia risk reduction may be 1 of the multiple goals of antihypertensive treatment in late-life (eg, prevention of ischemic heart disease, chronic kidney disease). A single measure of SBP or DBP at baseline had no significant association with late-life dementia risk, and, corroborating extant hypertension guidelines,⁴⁶ it seems that more than 1 measure is needed to inform treatment.

ARTICLE INFORMATION

Accepted for Publication: July 28, 2023.

Published: September 12, 2023. doi:10.1001/jamanetworkopen.2023.33353

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2023 Lennon MJ et al. *JAMA Network Open*.

Corresponding Author: Matthew J. Lennon, MD, Centre for Healthy Brain Aging, Discipline of Psychiatry & Mental Health, School of Clinical Medicine, University of New South Wales, High Street, Kensington, NSW 2066, Australia (matthew.lennon@unsw.edu.au).

Author Affiliations: Faculty of Medicine, University of New South Wales, Sydney, Australia (Lennon, Lam, Lipnicki, Crawford, Brodaty, Thalamuthu, Sachdev); Centre for Healthy Brain Aging, Discipline of Psychiatry & Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, Australia (Lennon, Lam, Lipnicki, Crawford, Brodaty, Thalamuthu, Sachdev); School of Psychology and Public Health, La Trobe University, Melbourne, Australia (Lam); The George Institute for Global Health, Sydney, Australia (Peters, Schutte); School of Biomedical Sciences, University of New South Wales, Sydney, Australia (Peters); School of Public Health, Imperial College London, London, United Kingdom (Peters); School of Population Health, University of New South Wales, Sydney, Australia (Schutte); Eastern Suburbs Older Persons' Mental Health Service, Sydney, Australia (Brodaty); Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, Centre for Ageing and Health at the University of Gothenburg, Gothenburg, Sweden (Rydberg-Sterner, Najar, Skoog); Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden (Rydberg-Sterner); Psychiatry, Cognition and Old Age Psychiatry Clinic, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden (Najar, Skoog); Institute of Social Medicine, Occupational Health and Public Health, Medical Faculty, University of Leipzig, Leipzig, Germany (Riedel-Heller, Röhr, Pabst); School of Psychology, Manawatu Campus, Massey University, Palmerston North, New Zealand (Röhr); Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland (Röhr); Department of Medicine and Psychiatry, Universidad de Zaragoza, Zaragoza, Spain (A. Lobo, De-la-Cámara, E. Lobo); Instituto de Investigación Sanitaria Aragón, Zaragoza, Spain (A. Lobo, De-la-Cámara, E. Lobo); Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain (A. Lobo, De-la-Cámara, E. Lobo); World Health Organization Collaborating Centre for Research and Training in Mental Health, Neuroscience, and Substance Abuse, Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria (Bello, Gureje, Ojagbemi); Department of Neurology, Albert Einstein College of Medicine, Bronx, New York (Lipton, Katz, Derby); Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York (Lipton, Derby); Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea (Kim, Han); Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea (Kim, Han); Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Korea (Kim); Workplace Mental Health Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea (Oh); Golgi Cenci Foundation, Abbiategrosso, Italy (Rolandi, Davin, Rossi); Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy (Rolandi); First Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Athens, Greece (Scarmeas); Department of Neurology, Columbia University, New York, New York (Scarmeas); Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece (Yannakoulia); Department of Neurology, University Hospital of Larissa, Larissa, Greece (Dardiotis); Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece (Dardiotis); Department of Psychiatry, Indiana University School of Medicine, Indianapolis (Hendrie); Indiana Alzheimer Disease Research Center, Indiana Alzheimer Disease Research Center, Indianapolis (Hendrie, S. Gao); Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis (S. Gao); Institut for Neurosciences of Montpellier, University Montpellier, National Institute for Health and Medical Research, Montpellier, France (Carrière, Ritchie); Institut du Cerveau Trocadéro, Paris, France (Ritchie); University of New South Wales, School of Psychology, Sydney, Australia (Anstey); Ageing Futures Institute, University of New South Wales, Sydney, Australia (Anstey); Neuroscience Research Australia, Sydney, Australia (Anstey); National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia (Cherbuin); Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Xiao, Yue, Li); Alzheimer's Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China (Xiao, Yue, Li); National Institute for Health and Medical Research U1094, Institut de Recherche pour le Développement UMR270, Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, University Limoges, Centre Hospitalier et Universitaire Limoges, Limoges, France (Guerchet, Preux, Aboyans); Department of Cardiology, Dupuytren 2 University Hospital, Limoges, France (Aboyans); School of Medicine, University of California, San Francisco (Haan); Robert N. Butler Columbia Aging Center, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York (Aiello); Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

(Ng, Nyunt, Q. Gao); Geriatric Education and Research Institute, Ministry of Health, Singapore, Singapore (Ng); Departamento de Psiquiatria, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil (Sczufca); Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia (Sachdev).

Author Contributions: Drs Lennon and Lipnicki had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Lennon, Lam, Crawford, Peters, Thalamuthu, Pabst, Dardiotis, Ritchie, Yue, Li, Haan, Nyunt, Q. Gao, Sachdev.

Acquisition, analysis, or interpretation of data: Lennon, Lam, Lipnicki, Schutte, Brodaty, Thalamuthu, Rydberg, Sterner, Najar, Skoog, Riedel-Heller, Roehr, A. Lobo, De-la-Cámara, E. Lobo, Bello, Gureje, Ojagbemi, Lipton, Katz, Derby, Kim, Han, Oh, Rolandi, Davin, Rossi, Scarmeas, Yannakoulia, Dardiotis, Hendrie, S. Gao, Carrière, Anstey, Cherbuin, Xiao, Guerchet, Preux, Aboyans, Aiello, Ng, Q. Gao, Sczufca, Sachdev.

Drafting of the manuscript: Lennon, Dardiotis, Hendrie, Yue, Nyunt, Q. Gao.

Critical review of the manuscript for important intellectual content: Lennon, Lam, Lipnicki, Crawford, Peters, Schutte, Brodaty, Thalamuthu, Rydberg, Sterner, Najar, Skoog, Riedel-Heller, Roehr, Pabst, A. Lobo, De-la-Cámara, E. Lobo, Bello, Gureje, Ojagbemi, Lipton, Katz, Derby, Kim, Han, Oh, Rolandi, Davin, Rossi, Scarmeas, Yannakoulia, Dardiotis, Hendrie, S. Gao, Carrière, Ritchie, Anstey, Cherbuin, Xiao, Li, Guerchet, Preux, Aboyans, Haan, Aiello, Ng, Sczufca, Sachdev.

Statistical analysis: Lennon, Lam, Crawford, Thalamuthu, Pabst, Bello, Dardiotis, Carrière, Nyunt, Sczufca.

Obtained funding: Brodaty, Skoog, Riedel-Heller, A. Lobo, Gureje, Katz, Derby, Kim, Hendrie, S. Gao, Ritchie, Anstey, Cherbuin, Yue, Guerchet, Ng, Q. Gao, Sczufca, Sachdev.

Administrative, technical, or material support: Lennon, Lipnicki, Brodaty, Rydberg, Sterner, Najar, Skoog, Roehr, A. Lobo, De-la-Cámara, E. Lobo, Ojagbemi, Kim, Han, Oh, Dardiotis, S. Gao, Ritchie, Anstey, Cherbuin, Li, Ng, Q. Gao.

Supervision: Schutte, Thalamuthu, Riedel-Heller, De-la-Cámara, Kim, Scarmeas, Yannakoulia, Dardiotis, Hendrie, Anstey, Preux, Haan, Sachdev.

Conflict of Interest Disclosures: Dr Peters reported receiving grants from the Australian National Health and Medical Research Council (NHMRC) and Mindgardens Neuroscience Network outside the submitted work. Dr Schutte reported receiving personal fees from Omron Healthcare, Servier, Abbott, and Sanofi outside the submitted work. Dr Brodaty reported receiving personal fees from Biogen, Eli Lilly, Eisai, Roche, Skin2Neuron, and Cranbrook Care and grants from the NHMRC (paid to institution) outside the submitted work. Dr A. Lobo reported receiving personal fees from Janssen. Dr Scarmeas reported receiving grants from Novo Nordisk and the National Institutes of Health outside the submitted work. Dr Aboyans reported receiving personal fees from Bayer Healthcare and Novo Nordisk outside the submitted work. Dr Sachdev reported serving as a consultant for Biogen and Roche. No other disclosures were reported.

Funding/Support: In Australia, the Cohort Studies of Memory in an International Consortium (COSMIC) project is funded by the NHMRC (grant No. APP1169489), which is awarded and governed by the Joint Programme–Neurodegenerative Disease Research (JPND). In the US, funding for COSMIC project is funded by the National Institutes of Health National Institute on Aging (NIA) (award No. 1RF1AG057531-01). The Epidemiology of dementia in Central Africa study was funded by the French National Research Agency (grant No. ANR-09-MNPS-009-01), the AXA Research Fund (grant 2012–Project Public Health Institute [Inserm]–PREUX Pierre-Marie), and the Limoges University Hospital through its Appel à Projet des Equipes Émergentes et Labellisées scheme. The Hellenic Longitudinal Investigation of Aging and Diet cohort was funded by the Alzheimer’s Association (grant No. IIRG-09-133014), European Social Fund (grant No. 189 10276/8/9/2011), and Greek Ministry of Health (grant No. DY2b/oik.51657/14.4.2009). The Leipzig Longitudinal Study of the Aged was funded by the Interdisciplinary Centre for Clinical Research at the University of Leipzig (grant No. 01KS9504). The Sydney Memory and Ageing study was funded by the NHMRC (grant No. APP350833, APP568969, and APP1093083). Funding for the Chinese Longitudinal Aging Study was from the Ministry of Science and Technology, National Pillar Program (grant No. 2009BAI77B03), and the National Key Clinical Disciplines at Shanghai Mental Health Center (Office of Medical Affairs, Ministry of Health, 2011-873). The H70 study was supported by AgeCap-Center for Aging and Health, Riksbankens Jubileumsfond, Forskningsrådet för hälsa, arbetsliv och välfärd, and the Swedish Brain Power. The Gothenburg H70 Birth Cohort Study data collection was supported by the Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, Epilife, Swedish Brain Power, The Alzheimer’s Association Zenith Award, the Alzheimer’s Association Stephanie B Overstreet Scholars, the Bank of Sweden Tercentenary Foundation, Stiftelsen Söderström-Königska Sjukhemmet, Stiftelsen för Gamla Tjänarinnor, Handlanden Hjalmar Svenssons Forskningsfond, and Stiftelsen Professor Bror Gadeliuss’ Minnesfond. Dr Najar was funded by Alzheimersfonden (grant No. AF-967865), the ALF-agreement (grant No. 72660), and Stiftelsens Hjalmar Svenssons forskningsfond (grant No. HJSV2022059 and HJSV2023023). The Ibadan Study of Aging was supported by Wellcome Trust (grant No. WT079662MF). The

Korean Longitudinal Study on Cognitive Aging and Dementia was supported by the Korean Health Technology R&D Project, Ministry of Health and Welfare, South Korea (grant No. H109C1379 [A092077]). Singapore Longitudinal Ageing Studies were supported by the Biomedical Research Council, Agency for Science, Technology and Research, Singapore (grant No. 03/1/21/17/214). The Zaragoza Dementia and Depression study was supported by the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, Madrid, Spain (grant No. 94/1562, 97/1321E, 98/0103, 01/0255, 03/0815, 06/0617, G03/128, 12/02254, 16/00896, and 19/01874), and the Fondo Europeo de Desarrollo Regional of the European Union and Gobierno de Aragón (grant No. B15.17R). The European Strategic Programme on Research in Information Technology project is financed by the regional government of Languedoc-Roussillon, the Agence National de Recherche Project 07 LVIE 004, and an unconditional grant from Novartis. The Einstein Aging Study is supported by the NIA (grant No. P01AG03949), the Czap Foundation, and the Max and Sylvia Marx Foundation. São Paulo Aging & Health Study was funded by the Wellcome Trust (grant No. GRO66133MA), UK and Fundação de Amparo à Pesquisa do Estado de São Paulo (grant No. 1998/12727-0). Dr Scazufca is supported by the Brazil National Council for Scientific and Technological Development (grant No. 307579/2019-0).

Role of the Funder/Sponsor: The NIA approved the initial plan for the COSMIC consortium but had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The other funders and sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Data Sharing Statement: See [Supplement 2](#).

Additional Information: The head of COSMIC is Dr Sachdev, and the study coordinator is Dr Lipnicki. The research scientific committee leads the scientific agenda of COSMIC and provides ongoing support and governance; it comprises member study leaders. The COSMIC research scientific committee and additional principal investigators are listed at <https://cheba.unsw.edu.au/consortia/cosmic/scientific-committee>.

REFERENCES

1. Bloch MJ. Worldwide prevalence of hypertension exceeds 1.3 billion. *J Am Soc Hypertens*. 2016;10(10):753-754. doi:10.1016/j.jash.2016.08.006
2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
3. Lennon MJ, Makkar SR, Crawford JD, Sachdev PS. Midlife hypertension and Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis*. 2019;71(1):307-316. doi:10.3233/JAD-190474
4. Forte G, De Pascalis V, Favieri F, Casagrande M. Effects of blood pressure on cognitive performance: a systematic review. *J Clin Med*. 2019;9(1):34. doi:10.3390/jcm9010034
5. van Dalen JW, Brayne C, Crane PK, et al. Association of systolic blood pressure with dementia risk and the role of age, U-shaped associations, and mortality. *JAMA Intern Med*. 2022;182(2):142-152. doi:10.1001/jamainternmed.2021.7009
6. Rajan KB, Barnes LL, Wilson RS, Weuve J, McAninch EA, Evans DA. Blood pressure and risk of incident Alzheimer's disease dementia by antihypertensive medications and APOE ε4 allele. *Ann Neurol*. 2018;83(5):935-944. doi:10.1002/ana.25228
7. Blanken AE, Nation DA. Does gender influence the relationship between high blood pressure and dementia: highlighting areas for further investigation. *J Alzheimers Dis*. 2020;78(1):23-48. doi:10.3233/JAD-200245
8. Ruitenberg A, Skoog I, Ott A, et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. *Dement Geriatr Cogn Disord*. 2001;12(1):33-39. doi:10.1159/000051233
9. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. *Am J Epidemiol*. 2002;156(5):445-453. doi:10.1093/aje/kwf074
10. Qiu C, von Strauss E, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. *Stroke*. 2004;35(8):1810-1815. doi:10.1161/01.STR.0000133128.42462.ef
11. Israeli-Korn SD, Masarwa M, Schechtman E, et al. Hypertension increases the probability of Alzheimer's disease and of mild cognitive impairment in an Arab community in northern Israel. *Neuroepidemiology*. 2010;34(2):99-105. doi:10.1159/000264828
12. Kimm H, Lee PH, Shin YJ, et al. Mid-life and late-life vascular risk factors and dementia in Korean men and women. *Arch Gerontol Geriatr*. 2011;52(3):e117-e122. doi:10.1016/j.archger.2010.09.004

13. Gabin JM, Tams K, Saltvedt I, Sund E, Holmen J. Association between blood pressure and Alzheimer disease measured up to 27 years prior to diagnosis: the HUNT Study. *Alzheimers Res Ther*. 2017;9(1):37. doi:10.1186/s13195-017-0262-x
14. Hayden KM, Zandi PP, Lyketsos CG, et al; Cache County Investigators. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. *Alzheimer Dis Assoc Disord*. 2006;20(2):93-100. doi:10.1097/O1.wad.0000213814.43047.86
15. Levine DA, Gross AL, Briceño EM, et al. Association between blood pressure and later-life cognition among Black and White individuals. *JAMA Neurol*. 2020;77(7):810-819. doi:10.1001/jamaneurol.2020.0568
16. Levine DA, Galecki AT, Langa KM, et al. Blood pressure and cognitive decline over 8 years in middle-aged and older Black and White Americans. *Hypertension*. 2019;73(2):310-318. doi:10.1161/HYPERTENSIONAHA.118.12062
17. Akushevich I, Kolpakov S, Yashkin AP, Kravchenko J. Vulnerability to hypertension is a major determinant of racial disparities in Alzheimer's disease risk. *Am J Hypertens*. 2022;35(8):745-751. doi:10.1093/ajh/hpac063
18. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. *Lancet*. 1996;347(9009):1141-1145. doi:10.1016/S0140-6736(96)90608-X
19. Joas E, Bäckman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. *Hypertension*. 2012;59(4):796-801. doi:10.1161/HYPERTENSIONAHA.111.182204
20. Peters R, Xu Y, Fitzgerald O, et al; Dementia risk REduCTion (DIRECT) collaboration. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. *Eur Heart J*. 2022;43(48):4980-4990. doi:10.1093/eurheartj/ehac584
21. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P. Generalizability of SPRINT results to the U.S. adult population. *J Am Coll Cardiol*. 2016;67(5):463-472. doi:10.1016/j.jacc.2015.10.037
22. Sheppard JP, Lown M, Burt J, et al. Generalizability of blood pressure lowering trials to older patients: cross-sectional analysis. *J Am Geriatr Soc*. 2020;68(11):2508-2515. doi:10.1111/jgs.16749
23. Ritchie K, Carrière I, Ritchie CW, Berr C, Artero S, Ancelin M-L. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. *BMJ*. 2010;341:c3885. doi:10.1136/bmj.c3885
24. Guaita A, Colombo M, Vaccaro R, et al. Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study. *BMC Geriatr*. 2013;13(1):98. doi:10.1186/1471-2318-13-98
25. Han JW, Kim TH, Kwak KP, et al. Overview of the Korean longitudinal study on cognitive aging and dementia. *Psychiatry Investig*. 2018;15(8):767-774. doi:10.30773/pi.2018.06.02
26. Guerchet M, Mbelesso P, Ndamba-Bandzouzi B, et al; EPIDEMCA group. Epidemiology of dementia in Central Africa (EPIDEMCA): protocol for a multicentre population-based study in rural and urban areas of the Central African Republic and the Republic of Congo. *Springerplus*. 2014;3(1):338. doi:10.1186/2193-1801-3-338
27. Hendrie HC, Ogunniyi A, Hall KS, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. *JAMA*. 2001;285(6):739-747. doi:10.1001/jama.285.6.739
28. Hall K, Gureje O, Gao S, et al. Risk factors and Alzheimer's disease: a comparative study of two communities. *Aust N Z J Psychiatry*. 1998;32(5):698-706. doi:10.3109/00048679809113126
29. Xiao S, Lewis M, Mellor D, et al. The China longitudinal ageing study: overview of the demographic, psychosocial and cognitive data of the Shanghai sample. *J Ment Health*. 2016;25(2):131-136. doi:10.3109/09638237.2015.1124385
30. Dardiotis E, Kosmidis MH, Yannakoulia M, Hadjigeorgiou GM, Scarmeas N. The Hellenic Longitudinal Investigation of Aging and Diet (HELIAD): rationale, study design, and cohort description. *Neuroepidemiology*. 2014;43(1):9-14. doi:10.1159/000362723
31. Katz MJ, Lipton RB, Hall CB, et al. Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. *Alzheimer Dis Assoc Disord*. 2012;26(4):335-343. doi:10.1097/WAD.0b013e31823dbcfc
32. Rydberg Sterner T, Ahlner F, Blennow K, et al. The Gothenburg H70 Birth cohort study 2014-16: design, methods and study population. *Eur J Epidemiol*. 2019;34(2):191-209. doi:10.1007/s10654-018-0459-8
33. Riedel-Heller SG, Busse A, Aurich C, Matschinger H, Angermeyer MC. Incidence of dementia according to DSM-III-R and ICD-10: results of the Leipzig Longitudinal Study of the Aged (LEILA75+), Part 2. *Br J Psychiatry*. 2001;179(3):255-260. doi:10.1192/bjp.179.3.255

34. Anstey KJ, Christensen H, Butterworth P, et al. Cohort profile: the PATH through life project. *Int J Epidemiol*. 2012;41(4):951-960. doi:10.1093/ije/dyr025
35. Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ. Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. *J Am Geriatr Soc*. 2003;51(2):169-177. doi:10.1046/j.1532-5415.2003.51054.x
36. Feng L, Gwee X, Kua EH, Ng TP. Cognitive function and tea consumption in community dwelling older Chinese in Singapore. *J Nutr Health Aging*. 2010;14(6):433-438. doi:10.1007/s12603-010-0095-9
37. Sczufca M, Menezes PR, Araya R, et al; Sao Paulo Ageing & Health Study. Risk factors across the life course and dementia in a Brazilian population: results from the Sao Paulo Ageing & Health Study (SPAH). *Int J Epidemiol*. 2008;37(4):879-890. doi:10.1093/ije/dyn125
38. Sachdev PS, Brodaty H, Reppermund S, et al; Memory and Ageing Study Team. The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. *Int Psychogeriatr*. 2010;22(8):1248-1264. doi:10.1017/S1041610210001067
39. Lobo A, Saz P, Marcos G, et al. The ZARADEMP Project on the incidence, prevalence and risk factors of dementia (and depression) in the elderly community: I: the context and the objectives. *Eur J Psychiatry*. 2005;19(1):31-39. doi:10.4321/S0213-61632005000100003
40. Stewart LA, Clarke M, Rovers M, et al; PRISMA-IPD Development Group. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA*. 2015;313(16):1657-1665. doi:10.1001/jama.2015.3656
41. Lipnicki DM, Makkar SR, Crawford JD, et al; for Cohort Studies of Memory in an International Consortium (COSMIC). Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: A COSMIC collaboration cohort study. *PLoS Med*. 2019;16(7):e1002853. doi:10.1371/journal.pmed.1002853
42. Samtani S, Mahalingam G, Lam BCP, et al; SHARED consortium for the Cohort Studies of Memory in an International Consortium (COSMIC). Associations between social connections and cognition: a global collaborative individual participant data meta-analysis. *Lancet Healthy Longev*. 2022;3(11):e740-e753. doi:10.1016/S2666-7568(22)00199-4
43. Mewton L, Visontay R, Hoy N, et al. The relationship between alcohol use and dementia in adults aged more than 60 years: a combined analysis of prospective, individual-participant data from 15 international studies. *Addiction*. 2023;118(3):412-424. doi:10.1111/add.16035
44. Sachdev PS, Lipnicki DM, Kochan NA, et al; COSMIC. COSMIC (Cohort Studies of Memory in an International Consortium): an international consortium to identify risk and protective factors and biomarkers of cognitive ageing and dementia in diverse ethnic and sociocultural groups. *BMC Neurol*. 2013;13(165):165. doi:10.1186/1471-2377-13-165
45. Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. *Stat Med*. 2017;36(5):855-875. doi:10.1002/sim.7141
46. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71(6):e13-e115.
47. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. *Arch Gen Psychiatry*. 1998;55(9):809-815. doi:10.1001/archpsyc.55.9.809
48. Therneau T. Package 'coxme.' Accessed August 9, 2023. <https://cran.r-project.org/web/packages/coxme/coxme.pdf>
49. Hughes D, Judge C, Murphy R, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. *JAMA*. 2020;323(19):1934-1944. doi:10.1001/jama.2020.4249
50. Ou YN, Tan CC, Shen XN, et al. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. *Hypertension*. 2020;76(1):217-225. doi:10.1161/HYPERTENSIONAHA.120.14993
51. Miller TA. Health literacy and adherence to medical treatment in chronic and acute illness: a meta-analysis. *Patient Educ Couns*. 2016;99(7):1079-1086. doi:10.1016/j.pec.2016.01.020
52. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. *Epidemiology*. 2011;22(5):646-659. doi:10.1097/EDE.0b013e31822708b5

53. Xu W, Tan L, Wang H-F, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. *J Neurool Neurosurg Psychiatry*. 2015;86(12):1299-1306. doi:10.1136/jnnp-2015-310548
54. O'Neal WT, Alam AB, Sandesara PB, et al. Sex and racial differences in cardiovascular disease risk in patients with atrial fibrillation. *PLoS One*. 2019;14(9):e0222147. doi:10.1371/journal.pone.0222147
55. Mital R, Bayne J, Rodriguez F, Ovbiagele B, Bhatt DL, Albert MA. Race and ethnicity considerations in patients with coronary artery disease and stroke: JACC focus seminar 3/9. *J Am Coll Cardiol*. 2021;78(24):2483-2492. doi:10.1016/j.jacc.2021.05.051
56. Shah NS, Ning H, Petito LC, et al. Associations of clinical and social risk factors with racial differences in premature cardiovascular disease. *Circulation*. 2022;146(3):201-210. doi:10.1161/CIRCULATIONAHA.121.058311
57. Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. *Lancet Neurol*. 2020;19(1):61-70. doi:10.1016/S1474-4422(19)30393-X
58. Bo M, Massaia M, Merlo C, Sona A, Canadè A, Fonte G. White-coat effect among older patients with suspected cognitive impairment: prevalence and clinical implications. *Int J Geriatr Psychiatry*. 2009;24(5):509-517. doi:10.1002/gps.4688
59. Guan J-W, Huang C-Q, Li Y-H, et al. No association between hypertension and risk for Alzheimer's disease: a meta-analysis of longitudinal studies. *J Alzheimers Dis*. 2011;27(4):799-807. doi:10.3233/JAD-2011-111160
60. Hassing LB, Hofer SM, Nilsson SE, et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. *Age Ageing*. 2004;33(4):355-361. doi:10.1093/ageing/afh100
61. Hebert LE, Scherr PA, Bennett DA, et al. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. *Neurology*. 2004;62(11):2021-2024. doi:10.1212/01.WNL.0000129258.93137.4B
62. Li G, Rhew AIC, Shofer JB, et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. *J Am Geriatr Soc*. 2007;55(8):1161-1167. doi:10.1111/j.1532-5415.2007.01233.x
63. Insel KC, Palmer RF, Stroup-Benham CA, Markides KS, Espino DV. Association between change in systolic blood pressure and cognitive decline among elderly Mexican Americans: data from the Hispanic established population for epidemiology study of the elderly. *Exp Aging Res*. 2005;31(1):35-54. doi:10.1080/03610730590882837
64. Kuo H, Jones RN, Milberg AWP, et al. Effect of blood pressure and diabetes mellitus on cognitive and physical functions in older adults: a longitudinal analysis of the advanced cognitive training for independent and vital elderly cohort. *J Am Geriatr Soc*. 2005;53(7):1154-1161. doi:10.1111/j.1532-5415.2005.53368.x
65. Schutte AE, Kollias A, Stergiou GS. Blood pressure and its variability: classic and novel measurement techniques. *Nat Rev Cardiol*. 2022;19(10):643-654. doi:10.1038/s41569-022-00690-0
66. Wang N, Harris K, Woodward M, et al; PROGRESS and ADVANCE collaborators. Clinical utility of short-term blood pressure measures to inform long-term blood pressure management. *Hypertension*. 2023;80(3):608-617. doi:10.1161/HYPERTENSIONAHA.122.20458
67. Del Giorno R, Balestra L, Heiniger PS, Gabutti L. Blood pressure variability with different measurement methods: Reliability and predictors: a proof of concept cross sectional study in elderly hypertensive hospitalized patients. *Medicine (Baltimore)*. 2019;98(28):e16347. doi:10.1097/MD.00000000000016347
68. Ernst ME, Chowdhury EK, Beilin LJ, et al; ASPREE Investigator Group. Long-term blood pressure variability and risk of cardiovascular disease events among community-dwelling elderly. *Hypertension*. 2020;76(6):1945-1952. doi:10.1161/HYPERTENSIONAHA.120.16209
69. Pioli MR, Ritter AM, de Faria AP, Modolo R. White coat syndrome and its variations: differences and clinical impact. *Integr Blood Press Control*. 2018;11:73-79. doi:10.2147/IBPC.S152761
70. Peters R, Peters J, Booth A, Anstey KJ. Trajectory of blood pressure, body mass index, cholesterol and incident dementia: systematic review. *Br J Psychiatry*. 2020;216(1):16-28. doi:10.1192/bjp.2019.156
71. Jefferson AL, Cambronero FE, Liu D, et al. Higher aortic stiffness is related to lower cerebral blood flow and preserved cerebrovascular reactivity in older adults. *Circulation*. 2018;138(18):1951-1962. doi:10.1161/CIRCULATIONAHA.118.032410
72. Picone DS, Schultz MG, Otahal P, et al; Invasive Blood Pressure Consortium. Influence of age on upper arm cuff blood pressure measurement. *Hypertension*. 2020;75(3):844-850. doi:10.1161/HYPERTENSIONAHA.119.13973
73. Walker KA, Sharrett AR, Wu A, et al. Association of midlife to late-life blood pressure patterns with incident dementia. *JAMA*. 2019;322(6):535-545. doi:10.1001/jama.2019.10575

74. Joas E, Bäckman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. *Hypertension*. 2012;59(4):796-801. doi:10.1161/HYPERTENSIONAHA.111.182204
75. Stewart R, Xue Q-L, Masaki K, et al. Change in blood pressure and incident dementia: a 32-year prospective study. *Hypertension*. 2009;54(2):233-240. doi:10.1161/HYPERTENSIONAHA.109.128744
76. Adesuyan M, Jani YH, Alsugeir D, et al. Antihypertensive agents and incident Alzheimer's disease: a systematic review and meta-analysis of observational studies. *J Prev Alzheimers Dis*. 2022;9(4):715-724. doi:10.14283/jpad.2022.77

SUPPLEMENT 1.

eMethods.

eTable 1. Ethics Approvals for Studies

eTable 2. Missingness and Dementia

eTable 3. Covariates in Studies

eTable 4. Comparing Covariates of the Hypertension Groups

eTable 5. Methods of Blood Pressure Measurement

eTable 6. Year Values Assigned to Educational Attainment, Harmonisation of Education Variables

eTable 7. Diabetes and Hypercholesterolemia Study Specific Details and Harmonization

eTable 8. Diagnostic Criteria and Method of Diagnosis for Dementia in Each Study

eTable 9. Hypertension History in Treated Compared With Untreated Populations

eTable 10. Two-Step Meta-Analysis

eTable 11. Interactions Between HT/AHT Status and Age, Sex, and Ethnicity Groups

eTable 12. Robustness of the HT/AHT Status Results in Later Age Groups

eTable 13. Interactions Between SBP/DBP and Age, Sex, and Ethnicity Groups

eTable 14. Interaction Terms Between HT/AHT Status and BP

eTable 15. HT/AHT Status and Dementia, Including Those With BP >160/100 mm Hg in the Untreated Hypertension Group

SUPPLEMENT 2.

Data Sharing Statement